EGRIFTA SV™ is a stabilized synthetic analogue of growth hormone releasing hormone (GHRH)
EGRIFTA SV™ is a newly FDA approved treatment* indicated for the reduction of Hard Belly in HIV-infected adult patients with lipodystrophy.
EGRIFTA SV™ specifically targets Hard Belly.

Mechanism of Action

Overview of the GH/IGF-1 axis1

*A newly approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.

†Also known as excess abdominal fat.

Growth hormone is not approved for the treatment of excess abdominal fat in patients with HIV with lipodystrophy.

References: 1. Longo DL, Fauci AS, Kasper DL, et al. Endocrinology and metabolism. In: Longo DL, Fauci AS, Kasper DL, et al., eds. Harrison’s Principles of Internal Medicine, Volume II. 18th ed. New York, NY: McGraw Hill Companies, Inc.; 2012:2890-2891. 2. Nam SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev. 2000;1(2):73-86. 3. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158.